Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir + daclatasvir in chronic hepatitis C genotype 1b with advanced liver disease
2014-003413-28Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of simeprevir and daclatasvir in hepatitis C virus infection, sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants with sustained virologic response 12 weeks after end of study drug treatment. Started Oct 2014; status: completed.
02
Drugs
simeprevirdaclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-003413-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003413-28.